BML-111|cas:78606-80-1|西域试剂

BML-111,98.0%

产品编号：Bellancom-100450| CAS NO：78606-80-1| 分子式：C₈H₁₆O₅| 分子量：192.21

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-100450		￥5050.00	杭州北京（现货）
Bellancom-100450		￥8050.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

BML-111

产品介绍

BML-111 一种脂蛋白 A₄ 类似物，是一种脂蛋白 A4 (lipoxin A₄) 受体激动剂。BML-111 可抑制血管紧张素转化酶 (ACE) 的活性，并增加血管紧张素转化酶 2 (ACE2) 的活性。BML-111 具有抗血管生成，抗肿瘤和抗炎的特性。

生物活性

BML-111, a lipoxin A₄ analog, is a lipoxin A₄ receptor agonist. BML-111 represses the activity of angiotensin converting enzyme (ACE) and increases the activity of angiotensinconverting enzyme 2 (ACE2). BML-111 has antiangiogenic, antitumor and anti-inflammatory properties.

体外研究

In H22 cells, BML-111 inhibits the production of vascular endothelial growth factor and reduces hypoxia-inducible factor-1α level.
BML-111 inhibits leukotriene B4-induced cellular migration with an IC₅₀ of 5 nM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

BML-111 (1 mg/kg; intraperitoneal injection; for 15 days; male Imprinting Control Region mice) treatment suppresses tumor-related angiogenesis and tumor growth in vivo. BML-111 also enhances the in situ apoptosis while inhibiting macrophage infiltration in tumor tissue.
BML-111 protects LPS-induced acute lung injury and LPS/D-GalN-induced acute liver injury. BML-111 represses the activity of ACE, but increases the activity of ACE2. BML-111 decreases the expression levels of ACE, AngII, and AngII type 1 receptor (AT1R), meanwhile increases the levels of ACE2, angiotensin-(1-7) (Ang-1-7), and Mas.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Imprinting Control Region mice (5-6-week-old,18-22 g) injected with H22 cells
Dosage:	1 mg/kg
Administration:	Intraperitoneal injection; injected 5 minutes before and 4 hours after H22 cell inoculation, then every 12 hours for 2 consecutive days, then daily in an additional 3 days and every other day for the last 10 days
Result:	Suppressed tumor-related angiogenesis and tumor growth in vivo.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Imprinting Control Region mice (5-6-week-old,18-22 g) injected with H22 cells
Dosage:	1 mg/kg
Administration:	Intraperitoneal injection; injected 5 minutes before and 4 hours after H22 cell inoculation, then every 12 hours for 2 consecutive days, then daily in an additional 3 days and every other day for the last 10 days
Result:	Suppressed tumor-related angiogenesis and tumor growth in vivo.

性状

Solid-liquid mixture

溶解性数据

In Vitro:

DMSO : 100 mg/mL (520.26 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	5.2026 mL	26.0132 mL	52.0264 mL
5 mM	1.0405 mL	5.2026 mL	10.4053 mL
10 mM	0.5203 mL	2.6013 mL	5.2026 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (13.01 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (13.01 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (13.01 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (13.01 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (13.01 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (13.01 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。